| WAT |
Report |
Adjusted EPS |
BEAT |
pred ~$3.08 vs. cons $3.00 |
MEDIUM |
| WAT |
Report |
Total reported revenue (incl. BDS) |
BEAT |
pred ~$1.64B vs. cons $1.623B |
MEDIUM |
| WAT |
Report |
Organic constant-currency revenue growth |
BEAT |
pred ~8.5% vs. cons 7.0% |
MEDIUM |
| WAT |
Guide |
FY2026 Adjusted EPS (raise) |
BETTER |
guide ~$14.65 vs. cons $14.55 (FY2026) |
MEDIUM |
| WAT |
Guide |
FY2026 total revenue (raise) |
BETTER |
guide ~$6.47B vs. cons $6.44B (FY2026) |
MEDIUM |
| WAT |
Guide |
Acquired BDS business growth inflection to positive (pro forma) |
BETTER |
guide ~+2% vs. cons ~+0.5% (Q2/H2 2026) |
MEDIUM |
| WAT |
Guide |
Q3 2026 Adjusted EPS (first synergy quarter) |
UNKNOWN |
guide ~$3.55 vs. cons $3.50 (Q3 2026) |
LOW |
| WAT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| WAT |
Return |
5-day cumulative residual |
+1.0% (FADE) |
A likely beat-and-raise (another BDS upside vs. conservatively-set numbers, legacy momentum, Q3 synergy arrival) drives a modest positive day-1 pop, but the setup is heavily de-risked: stock is up ~24% off the May low and sits near its late-July high (~$384 vs $375), so the bar is elevated and much of the good news is priced. The out-period math caps follow-through — management deliberately set implied H2 legacy organic growth at only ~6% (vs ~9% in H1) and acquired-business H2 assumptions just ~1.5pts above the Q2 guide, so even after a beat the conservative back-half framing limits upward estimate revisions and flattish YoY EPS optics (financing/dilution drag before synergies) invites partial give-back. Net: initial gains partially fade over 5 days. |
LOW |